Validation of the “Perceptions Regarding pRE-Symptomatic Alzheimer’s Disease Screening” (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening

Author:

Angelidou Ioanna Antigoni1,Stocker Hannah12,Beyreuther Konrad1,Teichmann Birgit1

Affiliation:

1. Network Aging Research, Heidelberg University, Heidelberg, Germany

2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany

Abstract

Background: Attitudes, motivations, and barriers to pre-symptomatic screening for Alzheimer’s disease (AD) in the general population are unclear, and validated measurement tools are lacking. Objective: Translation and validation of the German version of the “Perceptions regarding pRE-symptomatic Alzheimer’s Disease Screening” (PRE-ADS) questionnaire. Methods: A convenience sample (N = 256) was recruited via an online platform. Validation of the PRE-ADS-D consisted of assessments of reliability, structural validity using Principal Component Analysis (PCA) and Exploratory Factor Analysis (EFA) and construct validity using known-group tests. A subscale “Acceptability of Screening”, with 5 PRE-ADS-D items, was extracted to measure acceptance of screening in clinical practice. The STROBE checklist was used for reporting. Results: EFA revealed a three-factor model for the PRE-ADS-D. Acceptable to good internal consistency was found for the 25-item scale (α= 0.78), as well as for the three factors “Concerns about Screening” (α= 0.85), “Intention to be Screened” (α= 0.87), and “Preventive Health Behaviors” (α= 0.81). Construct validity was confirmed for both the 25-item PRE-ADS-D and the “Acceptability of Screening” scale (α= 0.91). Overall, 51.2% of the participants showed a preference for screening. Non-parametric tests were conducted to further explore group differences of the sample. Conclusions: The PRE-ADS-D is a reliable and valid tool to measure attitudes, motives, and barriers regarding pre-symptomatic dementia screening in the German-speaking general population. Additionally, the subscale “Acceptability of Screening” demonstrated good construct validity and reliability, suggesting its promising potential as a practical tool in clinical practice.

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience

Reference101 articles.

1. Alzheimer’s Disease International (2021) World Alzheimer Report 2021: Journey through the diagnosis of dementia . Alzheimer’s Disease International, London.

2. Fear about Alzheimer’s disease among Israeli and German laypersons, persons with Mild Neurocognitive Disorder and their relatives: A qualitative study;Werner;Int Psychogeriatr,2021

3. Rivastigmine for Alzheimer’s disease;Birks;Cochrane Database Syst Rev,2000

4. Lecanemab in early Alzheimer’s disease;van Dyck;N Engl J Med,2023

5. P4–173: The PRISM– PC questionnaire;Boustani;Alzheimers Dement,2006

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3